A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Launched by HOFFMANN-LA ROCHE · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment combination of three medications: glofitamab, gemcitabine, and oxaliplatin, for patients with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has either come back after treatment or did not respond to prior therapies. The study aims to understand how safe and effective this treatment is, particularly for patients from diverse racial and ethnic backgrounds in the U.S. If you or a loved one has been diagnosed with DLBCL and has already received at least one previous treatment, you might be eligible to participate.

To join the trial, participants need to have confirmed DLBCL that has either relapsed or is refractory, meaning it has not responded to treatment. They should have measurable signs of the disease and meet certain health criteria. If you decide to participate, you can expect to receive close monitoring and care from medical professionals throughout the study. It's also important to note that there are specific health conditions and previous treatments that could prevent someone from joining, so discussing eligibility with a healthcare provider is essential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed DLBCL, not otherwise specified (NOS)
• • Relapsed (disease that has recurred following a response that lasted ≥ 6 months after completion of the last line of therapy) or refractory ( disease that did not respond to or that progressed \< 6 months after completion of the last line of therapy) disease
• • At least one prior line of systemic therapy
• • Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
• • At least one bi-dimensionally measurable (\> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (\> 1 cm) extranodal lesion, as measured on CT scan
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Exclusion Criteria:
• • Prior enrollment in Study GO41944 (STARGLO; NCT04408638)
• • Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation
• • History of transformation of indolent disease to DLBCL
• • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS, as defined by 2016 WHO guidelines
• • Primary mediastinal B-cell lymphoma
• • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
• • Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
• • Prior treatment with gemcitabine or oxaliplatin
• • Peripheral neuropathy or paresthesia assessed to be Grade \>/= 2 according to NCI CTCAE v5.0 at enrollment
• • Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
• • Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
• • Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
• • Prior CNS involvement that has been definitively treated and confirmed via MRI or cerebrospinal fluid analysis to be in complete remission is permissible
• • Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
• • History of other primary malignancy, with exceptions defined by the protocol
• • Significant or extensive cardiovascular disease, or significant pulmonary disease
• • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (exclusing fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment
• • Documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 6 months of first study treatment, or positive SARS-CoV-2 test within 7 days prior to enrollment
• • Suspected or latent tuberculosis
• • Positive test results for hepatitis B (HBV) or hepatitis C (HCV)
• • Known or suspected chronic active Epstein-Barr viral infection
• • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
• • Known history of progressive multifocal leukoencephalopathy
• • Prior solid organ transplantation
• • Prior allogenic stem cell transplant
• • Active autoimmune disease requiring treatment
• • Prior treatment with systemic immunosuppressive medications within 4 weeks prior to first dose of study treatment
• • Ongoing systemic corticosteroid use which, in the opinion of the investigator, puts the patient at increased risk of steroid-related iatrogenic adrenal insufficiency
• • Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
• • Clinically significant history of cirrhotic liver disease